Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp374 | Other diseases of bone and mineral metabolism | ECTS2014

Clinical presentation of Paget's disease: evaluation of a contemporary cohort and systematic review

Tan Adrian , Ralston Stuart

Background: The prevalence and severity of Paget’s disease of bone (PDB) have fallen over recent years but it is unclear if this has impacted on disease presentation. Here we evaluated the presentation of PDB in a contemporary cohort and conducted a systematic review of MEDLINE on the mode of presentation.Methods: The presenting features of PDB were recorded in 87 patients who had presented to a specialist clinic between 2005 and 2013. The systemati...

ba0005p414 | Osteoporosis: treatment | ECTS2016

Teriparatide reduces the risk of vertebral fractures compared with standard care in patients with severe osteoporosis

Riches Philip , Calero Ismael , Ralston Stuart

Objectives: Treatment outcomes in patients treated with teriparatide were compared to standard care in patients with severe osteoporosis (bone mineral density T score of −4 or less).Methods: An observational study was performed of patients attending a specialist osteoporosis service and who were initiated on teriparatide (n=324). Patients that met criteria for teriparatide but declined treatment, were already established on a bisp...

ba0005p442 | Other diseases of bone and mineral metabolism | ECTS2016

Investigation of the Paget’s disease susceptibility locus on chromosome 15q24 using targeted next generation DNA sequencing approach

Wani Sachin , Ralston Stuart , Albagha Omar

Paget’s disease of bone (PDB) is a common disease characterised by focal abnormalities in bone turnover. Previous GWAS identified a susceptibility locus for PDB on chromosome 15q24 tagged by a coding SNP rs5742915 (p.Phe645Leu) located in PML. The aim of this study was to fine map this locus to identify functional genetic variants that predispose to PDB using targeted DNA sequencing and functional analysis in bone cells.A 200 kb region surr...

ba0001oc3.1 | Osteoporosis pathophysiology and genetics | ECTS2013

Heavy cannabis use negatively impacts on bone density: a population based prospective study

Sophocleous Antonia , McKenzie James , Robertson Roy , Ralston Stuart H

The endocannabinoid system has important effects on bone mass and bone turnover. Mice with targeted inactivation of type 1 (CB1) and type 2 (CB2) cannabinoid receptors develop osteoporosis with increasing age raising the possibility that cannabinoid receptor agonists might protect against age-related bone loss. Since cannabis is the most widely used illegal drug and its main psychotropic component -Δ9-tetrahydrocannabinol (THC)- is an agonist at CB1 and CB2 receptors, we ...

ba0001pp230 | Cell biology: osteoclasts and bone resorption | ECTS2013

Depletion of the autophagy adaptor OPTN leads to increased osteoclast formation, fusion and survival as well as increased NF-κB activation in vitro

Obaid Rami , Wani Sachin , Ralston Stuart , Albagha Omar

OPTN encodes a cytoplasmic protein optineurin which has been shown to play a role in autophagy. Recent GWAS studies have shown that variants within OPTN are associated with the risk of Paget’s disease of bone, a disease characterized by focal areas of increased bone turnover due to increased osteoclast activity, suggesting a possible role of OPTN in the regulation of bone metabolism.The aim of this study was to investigate the role of optineurin in ...

ba0001pp495 | Other diseases of bone and mineral metabolism | ECTS2013

Long-term effects of symptomatic vs intensive bisphosphonate therapy for Paget's disease of bone: the PRISM-EZ study

Goodman Kirsteen , MacLennan Graeme , Fraser William , Selby Peter , Ralston Stuart

Paget’s disease of bone (PDB) is a common metabolic bone disease characterised by increased and disorganised bone remodelling affecting one or more skeletal sites. Bisphosphonates are highly effective at suppressing bone turnover in PDB but it remains unclear whether greater suppression of bone turnover improves clinical outcome. In the PRISM study, we previously reported that PDB patients randomised to ‘intensive’ treatment aimed at normalising alkaline phospha...